If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Holding(s) in Company

2 Jun 2009 07:00

RNS Number : 1645T
GW Pharmaceuticals PLC
01 June 2009
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

GW Pharmaceuticals

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation:

 Prudential plc group of companies

4. Full name of shareholder(s) (if different from 3.):

 See attached schedule

5. Date of the transaction and date on which the threshold is crossed or reached:

 29 May 2009

6. Date on which issuer notified:

 01 June 2009

7. Threshold(s) that is/are crossed or reached:

 10%

  

8. Notified details:

A: Voting rights attached to shares

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

 GB0030544687

 12,070,000

 12,070,000

 13,070,000

 13,070,000

 

 10.82%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights

 

 

 

 

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 13,070,000

 10.82%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

 Prudential plc (parent Company)

M&G Group Limited (wholly owned Subsidiary of Prudential plc)

M&G Limited (wholly owned subsidiary of M&G Group Limited)

M&G Investment Management Limited (wholly owned subsidiary of M&G Limited)

M&G Securities Limited (wholly owned subsidiary of M&G Limited)

Proxy Voting:

10. Name of the proxy holder:

 N/A

11. Number of voting rights proxy holder will cease to hold:

 N/A

12. Date on which proxy holder will cease to hold voting rights:

 N/A

13. Additional information:

 

14. Contact name:

 Dipesh Varsani/ Mark Thomas

M&G Investment Management Limited

15. Contact telephone number:

 020 7548 3261 / 020 7548 3266

Notifiable Position Report for GW PHARMACEUTICALS ORD GBP0.001 as at 29 May 2009
 
Percentage holdings are calculated using an issued share capital of 120,785,335 ORD GBP0.001 shares
 
 
Registered Holder
Holding
 
Prudential plc 
 
13,070,000 
10.82

Total Notifiable Interest

 

 NORTRUST NOMINEE LTD A/C MKK01
10,951,111
 
 
 
 PRUCLT HSBC GIS NOM(UK) PPL AC
2,118,889
 
 
 
 
 
 
 
M&G Group Limited
 
13,070,000
10.82
 
 
 NORTRUST NOMINEE LTD A/C MKK01
10,951,111
 
 
 
 PRUCLT HSBC GIS NOM(UK) PPL AC
2,118,889
 
 
 
 
 
 
 
M&G Investment Management Limited
 
13,070,000
10.82
 
 
 NORTRUST NOMINEE LTD A/C MKK01
10,951,111
 
 
 
 PRUCLT HSBC GIS NOM(UK) PPL AC
2,118,889
 
 
 
 
 
 
 
M&G Limited
 
13,070,000
10.82
 
 
 NORTRUST NOMINEE LTD A/C MKK01
10,951,111
 
 
 
 PRUCLT HSBC GIS NOM(UK) PPL AC
2,118,889
 
 
 
 
 
 
 
M&G Securities Limited
 
10,951,111
9.06
 
 
 NORTRUST NOMINEE LTD A/C MKK01
10,951,111
 
 
This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAXKFEEPNEFE
Date   Source Headline
1st Dec 201611:15 amRNSAmerican Society of Epilepsy Annual Meeting
30th Nov 20161:00 pmRNSNotice of Q4 and year-end results
24th Nov 20167:30 amRNSHolding(s) in Company
22nd Nov 20161:00 pmRNSPresenting at Piper Jaffray Healthcare Conference
18th Nov 20169:31 amRNSHolding(s) in Company
11th Nov 20165:01 pmRNSHolding(s) in Company
10th Nov 201611:03 amRNSDirector/PDMR Shareholding
3rd Nov 20161:58 pmRNSDirector/PDMR Shareholding
3rd Nov 20167:50 amRNSHolding(s) in Company
3rd Nov 20167:47 amRNSHolding(s) in Company
2nd Nov 20165:05 pmRNSDirector/PDMR Shareholding
1st Nov 20169:58 amRNSDirector/PDMR Shareholding
31st Oct 20163:29 pmRNSHolding(s) in Company
31st Oct 20162:59 pmRNSTotal Voting Rights
31st Oct 20168:25 amRNSHolding(s) in Company
28th Oct 20164:58 pmRNSDirector Stock Trading Plan
28th Oct 20164:57 pmRNSDirector/PDMR Shareholding
26th Oct 20165:26 pmRNSDirector/PDMR Shareholding
25th Oct 20165:43 pmRNSDirector/PDMR Shareholding
21st Oct 20164:37 pmRNSPosting of Shareholder Circular
20th Oct 20163:30 pmRNSHolding(s) in Company
19th Oct 20167:00 amRNSIntention to Trade Exclusively on NASDAQ
7th Oct 201610:22 amRNSDirector Stock Trading Plan - Replacement
6th Oct 20166:01 pmRNSDirector Stock Trading Plan
30th Sep 20161:48 pmRNSTotal Voting Rights
26th Sep 201611:57 amRNSSecond Positive Phase 3 Trial for Epidiolex in LGS
14th Sep 20165:27 pmRNSDirector/PDMR Shareholding
7th Sep 201612:00 pmRNSPresenting at Morgan Stanley Healthcare Conference
31st Aug 201612:18 pmRNSTotal Issued Share Capital
17th Aug 20168:56 amRNSBlock listing Interim Review
9th Aug 201612:00 pmRNS3rd Quarter Results
9th Aug 201612:00 pmRNSNotification of Future Change to Board
2nd Aug 201612:00 pmRNSNotice of Results
29th Jul 201610:58 amRNSTotal Voting Rights
25th Jul 20167:57 amRNSHolding(s) in Company
21st Jul 201610:08 amRNSHolding(s) in Company
21st Jul 201610:04 amRNSHolding(s) in Company
19th Jul 20169:37 amRNSTotal Voting Rights
18th Jul 20164:15 pmRNSClosing of U.S. Public Offering Raising $289.8m
13th Jul 20167:00 amRNSUS Public Offering of ADSs Raising $252.0 Million
13th Jul 20167:00 amRNSProposed Public Offering of ADSs
1st Jul 20163:14 pmRNSHolding(s) in Company
1st Jul 20168:03 amRNSHolding(s) in Company
30th Jun 20163:22 pmRNSTotal Voting Rights
28th Jun 201612:14 pmRNSHolding(s) in Company
27th Jun 201612:07 pmRNSSecond Price Monitoring Extn
27th Jun 201612:02 pmRNSPrice Monitoring Extension
27th Jun 201612:00 pmRNSPositive Phase 3 Pivotal Trial Results
27th Jun 201610:00 amRNSHolding(s) in Company
23rd Jun 20167:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.